50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

PureTech reports positive LYT-200 trial results in AML/MDS

Published 12/09/2024, 02:05 AM

SAN DIEGO - PureTech Health plc (NASDAQ:PRTC, LSE:PRTC) shared promising data from a Phase 1b trial of LYT-200, a novel anti-galectin-9 monoclonal antibody, at the American Society of Hematology (ASH) Annual Meeting. The trial involved patients with relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), showing the drug's safety and efficacy both as a standalone treatment and in combination with current standard-of-care therapies.

Patients with AML/MDS who have relapsed or shown resistance to prior treatments received LYT-200 in varying doses. Results indicated that 59% of evaluable patients achieved stable disease or better, with two partial responses noted. The average duration of treatment was over two months, surpassing the standard survival rate for patients resistant to venetoclax and hypomethylating agents (HMA).

In combination with venetoclax/HMA, LYT-200 showed an 80% rate of stable disease or better, with two complete responses and one morphologic leukemia-free state. The combination treatment also benefited patients with specific mutations like KRAS/NRAS, supporting the potential of LYT-200 to enhance the efficacy of existing AML treatments.

LYT-200's dual-action mechanism was highlighted, which includes direct cancer cell apoptosis and re-activation of the immune system's anti-cancer effectors. Pharmacodynamic assessments further validated this dual mode of action, identifying cellular pathways and immune cell types that may be key to the drug's response.

Based on these findings, PureTech plans to advance LYT-200 into a Phase 2 clinical trial, positioning it as a potential first-line treatment for AML/MDS patients. The company, which focuses on developing medicines for devastating diseases, has previously indicated that LYT-200 will be developed through its Founded Entity, Gallop Oncology.

The data presented is based on a press release statement from PureTech Health plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.